Based on research from the University of North Carolina and seeded by Hatteras Venture Partners, the start-up is developing cyclin-dependent kinase (CDK) 4/6 inhibitors for use in protecting the bone marrow of cancer patients receiving chemotherapy. The funding should bring the biotech through IND filing and into Phase I work.

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

The latest news on digital health partnerships and research.